Remedy Entertainment
Last analysed 2 Oct 2026 · Anchored at $19.17
Remedy is attractive again around $19.17, with CONTROL Resonant validating product and publishing execution while unit-sales economics remain unproven.
Investment profile
Green team
The case for
CONTROL Resonant has materially de-risked the thesis. Critics settled around 83-84, Steam reviews are roughly 90% positive, Steam peak concurrent users reached 42,799, and PlayStation tracking remained strong across multiple markets. The launch was good rather than blockbuster, but it largely clears the previous risk that Remedy could spend heavily on another poorly received product.
More importantly, Remedy has partially validated its transition from developer to owner-publisher. It successfully executed a global self-published launch, while Annapurna funded 50% of Resonant's roughly $56.3m development budget. At approximately $247.5m enterprise value, management's 2027 target economics would make the valuation attractive if Resonant sales and the broader release pipeline convert product quality into sustained profitability.
Red team
The case against
The missing evidence is commercial. Remedy has not disclosed an official Resonant sales milestone, third-party Steam ownership estimates vary widely, and strong reviews do not reveal actual console mix, net revenue, refunds or Remedy's exact post-recoup economics with Annapurna. A good game can still become only a mediocre investment if unit sales fail to scale.
The business also remains hit-driven. Firebreak produced roughly a $16.8m impairment, the balance sheet carries an approximately $16.9m Tencent convertible with 8% PIK interest, and employee options create additional dilution risk. Resonant has reduced product and publishing-execution risk, but Remedy has not yet demonstrated smooth, repeatable high-return compounding across releases.
valu8 verdict
Remedy is attractive again around $19.17, with CONTROL Resonant validating product and publishing execution while unit-sales economics remain unproven. The thesis has improved because product risk fell while the share price also declined, creating better asymmetry without requiring a blockbuster outcome. A starter or partial add is supported at the current level, while full sizing should wait for an official Resonant sales milestone or clearer post-launch financial evidence.
The debate
- Has CONTROL Resonant validated Remedy's ability to successfully launch and self-publish major owned IP?
- Will Resonant sell enough units to validate the economics of Remedy's self-publishing strategy?unresolved
- Can Remedy turn overlapping catalogue, owned-IP launches and partner projects into more predictable earnings?unresolved
- Is management's 2027 profitability target achievable on a sustainable basis?unresolved
Asymmetry
| Scenario | Return % | Probability | Condition |
|---|---|---|---|
| Downside | -31.7% | 30% | Resonant sales stall or deliver only mediocre commercial conversion despite good product reception. |
| Base | +35% | 45% | Current analyst unit expectations broadly play out and Resonant becomes a solid commercial success. |
| Upside | +87.8% | 25% | Resonant materially beats expectations or CONTROL develops into a substantially larger mainstream franchise. |
Downside
- Return %
- -31.7%
- Probability
- 30%
- Condition
- Resonant sales stall or deliver only mediocre commercial conversion despite good product reception.
Base
- Return %
- +35%
- Probability
- 45%
- Condition
- Current analyst unit expectations broadly play out and Resonant becomes a solid commercial success.
Upside
- Return %
- +87.8%
- Probability
- 25%
- Condition
- Resonant materially beats expectations or CONTROL develops into a substantially larger mainstream franchise.
Green team was right
- Resonant materially reduced product-quality and publishing-execution risk through a successful multi-platform launch and strong player reception.
- The CONTROL ownership and co-funded self-publishing structure gives Remedy materially better economics than its historical publisher-funded model.
- The lower share price combined with reduced product risk has improved the investment asymmetry.
Red team was right
- Strong product reception does not prove commercial success, and official Resonant unit sales remain undisclosed.
- Firebreak demonstrates that Remedy remains exposed to large impairments when individual projects fail.
- The business remains hit-driven and has not yet demonstrated sustainable 30% EBITDA margins across a full cycle.
Deciding factor
Verified Resonant unit sales and revenue conversion will determine whether Remedy's newly validated publishing capability also produces attractive and repeatable economics.
What would change this
- Approximately 2 million Resonant units by year-end would materially strengthen the self-publishing and 2027 profitability thesis.
- A result closer to 1 million to 1.3 million units would weaken the current commercial bull case despite positive game reception.
- Evidence in the November report or subsequent disclosures that Resonant is generating strong profits without balance-sheet deterioration would support further conviction.
- A decline toward roughly $15.75-$16.88 without thesis deterioration would materially improve the asymmetry.
Key risk
Resonant proves to be a well-reviewed game but converts into insufficient unit sales and profitability to validate Remedy's broader self-publishing economics.
Not covered
The most material missing evidence is verified CONTROL Resonant unit sales and realized publishing economics, including the exact post-recoup revenue split with Annapurna.
Product quality is validated, but sales must now prove the publishing economics.